Life years lost by childhood cancer treatment and health related late effects among childhood cancer survivors.

Autor: Charrier T; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France; INSERM, U900, Institut Curie, PSL Research University, Saint-Cloud, France. Electronic address: thibaud.charrier@gustaveroussy.fr., Haddy N; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France; Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, Villejuif F-94805, France., Fresneau B; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; Gustave Roussy, Department of Children and Adolescent Oncology, Villejuif F-94805, France., Schwartz B; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France; Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, Villejuif F-94805, France., Journy N; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France; Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, Villejuif F-94805, France., Demoor-Goldschmidt C; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France; Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, Villejuif F-94805, France; Department of Pediatric Oncology, Centre Hospitalier Universitaire,4 rue Larrey, Angers 49000, France; Department of radiotherapy, Centre François Baclesse, 3 av du Général Harris, Caen 14000, France; Department of supportive care, Centre François Baclesse, 3 av du Général Harris, Caen 14000, France., Diallo I; Department of Radiation Oncology, Gustave Roussy, Villejuif, Paris, France; Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Villejuif, I^le-de-France, France., Aerts I; SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, Paris, France., Doz F; SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, Paris, France; Université Paris Cité, Paris, France., Souchard V; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France; Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, Villejuif F-94805, France., Vu-Bezin G; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France; Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, Villejuif F-94805, France., Laprie A; Department of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France., Lemler S; Université Paris-Saclay, CentraleSupélec, Mathématiques et Informatique pour la Complexité et les Systémes, Gif-sur-Yvette 91190, France., Letort V; Université Paris-Saclay, CentraleSupélec, Mathématiques et Informatique pour la Complexité et les Systémes, Gif-sur-Yvette 91190, France., Rubino C; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France; Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, Villejuif F-94805, France., Kamary K; Université Paris-Saclay, CentraleSupélec, Mathématiques et Informatique pour la Complexité et les Systémes, Gif-sur-Yvette 91190, France., Aba NM; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France., Ducos C; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France., Locquet M; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France; Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, Villejuif F-94805, France., Vathaire F; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France; Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, Villejuif F-94805, France., Allodji RS; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif 94807, France; CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Villejuif, France; Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, Villejuif F-94805, France; Polytechnic School of Abomey-Calavi (EPAC), University of Abomey-Calavi, 01 P.O. Box 2009, Cotonou, Benin., Latouche A; INSERM, U900, Institut Curie, PSL Research University, Saint-Cloud, France; Conservatoire National des Arts et Métiers, Paris, France.
Jazyk: angličtina
Zdroj: Cancer epidemiology [Cancer Epidemiol] 2024 Dec; Vol. 93, pp. 102692. Date of Electronic Publication: 2024 Nov 07.
DOI: 10.1016/j.canep.2024.102692
Abstrakt: Background: Identifying risk factors contributing the most to mortality of childhood cancer survivors is essential to guide harm reduction efforts in childhood cancer treatments, and long-term follow-up of childhood cancer survivors.
Methods: We assessed Life Years Lost from childhood cancer treatments and their health-related late effects among the French Childhood Cancer Survivors Study, a cohort of 7670 5-year childhood cancer survivors. Using a landmark strategy, we also assessed time-varying effects of risk factors, and how the multi-morbidity affects life years lost.
Results: We found subsequent malignant neoplasm (9.0 years [95 %CI: 4.3-13.7]), severe cardiac disease (8.0 years [95 %CI: 1.2-14.9]), and the use of radiotherapy (6.0 years [95 %CI: 4.7-7.3]) to be the highest contributors to Life Years Lost among childhood cancer survivors. We found no interaction impact on life years lost between health related late effects considered.
Conclusions: Those findings suggest that radiotherapy is the root cause of early mortality among childhood cancer survivors. Moreover patients experiencing a subsequent malignant neoplasm or a cardiac disease should be monitored closely after the event, as comorbidity is common and causes premature deaths.
Competing Interests: Declaration of Competing Interest None
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: